Community Trust & Investment Co. Acquires 14,258 Shares of Boston Scientific Corporation $BSX

Community Trust & Investment Co. lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 6.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 221,836 shares of the medical equipment provider’s stock after acquiring an additional 14,258 shares during the period. Community Trust & Investment Co.’s holdings in Boston Scientific were worth $9,683,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of BSX. BlackRock Inc. purchased a new position in Boston Scientific during the 2nd quarter worth $5,534,781,000. Primecap Management Co. CA purchased a new position in shares of Boston Scientific in the second quarter worth $2,156,233,000. Janus Henderson Group PLC grew its stake in Boston Scientific by 5.2% during the 4th quarter. Janus Henderson Group PLC now owns 12,589,385 shares of the medical equipment provider’s stock valued at $1,200,404,000 after purchasing an additional 617,515 shares during the last quarter. Amundi lifted its holdings in shares of Boston Scientific by 13.8% during the first quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock worth $886,213,000 after purchasing an additional 1,707,754 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its position in Boston Scientific by 25.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock worth $871,702,000 after buying an additional 2,856,040 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on BSX. UBS Group lowered their price target on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Jefferies Financial Group dropped their price target on shares of Boston Scientific from $67.00 to $60.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Wells Fargo & Company dropped their target price on shares of Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating on the stock in a research report on Wednesday, September 23rd. Mizuho set a $55.00 price objective on Boston Scientific in a research note on Tuesday. Finally, Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $68.23.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig purchased 5,000 shares of the firm’s stock in a transaction on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director David C. Habiger acquired 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have acquired 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $44.17 on Friday. The business’s 50-day moving average is $46.16 and its two-hundred day moving average is $49.80. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a 1 year low of $41.38 and a 1 year high of $105.65. The firm has a market capitalization of $64.02 billion, a P/E ratio of 17.88, a P/E/G ratio of 1.04 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the previous year, the business earned $0.75 earnings per share. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts anticipate that Boston Scientific Corporation will post 3.24 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.